These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7476169)

  • 1. Gene replacement by homologous recombination in Mycobacterium bovis BCG.
    Norman E; Dellagostin OA; McFadden J; Dale JW
    Mol Microbiol; 1995 May; 16(4):755-60. PubMed ID: 7476169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Genome Region of Difference 4 (RD4) on Mycobacterial Virulence and BCG Efficacy.
    Ru H; Liu X; Lin C; Yang J; Chen F; Sun R; Zhang L; Liu J
    Front Cell Infect Microbiol; 2017; 7():239. PubMed ID: 28642843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel vaccination strategies based on recombinant Mycobacterium bovis BCG.
    Dietrich G; Viret JF; Hess J
    Int J Med Microbiol; 2003 Feb; 292(7-8):441-51. PubMed ID: 12635927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of avirulent mutants of Mycobacterium bovis with vaccine properties by the use of illegitimate recombination and screening of stationary-phase cultures.
    Collins DM; Wilson T; Campbell S; Buddle BM; Wards BJ; Hotter G; de Lisle GW
    Microbiology (Reading); 2002 Oct; 148(Pt 10):3019-3027. PubMed ID: 12368435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An esat6 knockout mutant of Mycobacterium bovis produced by homologous recombination will contribute to the development of a live tuberculosis vaccine.
    Wards BJ; de Lisle GW; Collins DM
    Tuber Lung Dis; 2000; 80(4-5):185-9. PubMed ID: 11052907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis.
    Mahairas GG; Sabo PJ; Hickey MJ; Singh DC; Stover CK
    J Bacteriol; 1996 Mar; 178(5):1274-82. PubMed ID: 8631702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of guinea pigs with nutritionally impaired avirulent mutants of Mycobacterium bovis protects against tuberculosis.
    De Lisle GW; Wilson T; Collins DM; Buddle BM
    Infect Immun; 1999 May; 67(5):2624-6. PubMed ID: 10225931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recA deletion mutant of Mycobacterium bovis BCG confers protection equivalent to that of wild-type BCG but shows increased genetic stability.
    Sander P; Böttger EC; Springer B; Steinmann B; Rezwan M; Stavropoulos E; Joseph Colston M
    Vaccine; 2003 Oct; 21(27-30):4124-7. PubMed ID: 14505891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Mycobacterium bovis BCG.
    Bastos RG; Borsuk S; Seixas FK; Dellagostin OA
    Vaccine; 2009 Nov; 27(47):6495-503. PubMed ID: 19720367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of vaccines against tuberculosis in the relation to genetic variability of Mycobacterium bovis BCG strains].
    Prygiel M; Janaszek-Seydlitz W; Bucholc B
    Przegl Epidemiol; 2011; 65(4):621-8. PubMed ID: 22390050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on gene knock-out in Mycobacterium BCG].
    Chen XY; Li CY; Ma Y; Liu C; Wang JH; Zhang XF; Chang ZY
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Mar; 27(3):183-7. PubMed ID: 15130330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex.
    Collins DM
    Immunol Cell Biol; 2000 Aug; 78(4):342-8. PubMed ID: 10947858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterium bovis BCG moreau is naturally deficient in homologous recombination.
    Schwarz MGA; Corrêa PR; Malaga W; Guilhot C; Mendonça-Lima L
    Tuberculosis (Edinb); 2020 Jul; 123():101956. PubMed ID: 32741533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation of BCG with plasmid DNA.
    Lugosi L; Jacobs W; Bloom BR
    Acta Leprol; 1989; 7 Suppl 1():256-7. PubMed ID: 2503999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti.
    Pym AS; Brodin P; Brosch R; Huerre M; Cole ST
    Mol Microbiol; 2002 Nov; 46(3):709-17. PubMed ID: 12410828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy.
    Liu J; Tran V; Leung AS; Alexander DC; Zhu B
    Hum Vaccin; 2009 Feb; 5(2):70-8. PubMed ID: 19164935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Auxotrophic complementation as a selectable marker for stable expression of foreign antigens in Mycobacterium bovis BCG.
    Borsuk S; Mendum TA; Fagundes MQ; Michelon M; Cunha CW; McFadden J; Dellagostin OA
    Tuberculosis (Edinb); 2007 Nov; 87(6):474-80. PubMed ID: 17888740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis vaccine strain Mycobacterium bovis BCG Russia is a natural recA mutant.
    Keller PM; Böttger EC; Sander P
    BMC Microbiol; 2008 Jul; 8():120. PubMed ID: 18637199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The uraA locus and homologous recombination in Mycobacterium bovis BCG.
    Aldovini A; Husson RN; Young RA
    J Bacteriol; 1993 Nov; 175(22):7282-9. PubMed ID: 8226675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.